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Abstract
AIM
To characterize antiviral therapy eligibility among he-
patitis B virus (HBV)-infected adults at a university 
hospital in Zambia.
METHODS
Hepatitis B surface antigen-positive adults (n = 160) who 
were hIV-negative and referred to the hospital after a 
routine or clinically-driven HBV test were enrolled. Alanine 
Aminotransferase (ALT), Aspartate Aminotransferase 
(AST), platelet count, hepatitis B e-antigen, and HBV 
DNA were measured. Liver fibrosis/cirrhosis was asses-
sed by physical examination, AST-to-platelet ratio index, 
and transient elastography. In antiviral therapy-naïve 
individuals, we described hBV stages and antiviral 
therapy eligibility per World health Organization (WhO) 
and by hBV test (routine vs clinical). Elevated ALT was > 
19 in women and > 30 U/L in men. Among treatment-
experienced individuals, we described medication side 
effects, adherence, and viral suppression.
RESULTS
The median age was 33 years, 71.9% were men, and 
30.9% were diagnosed with HBV through a clinically-
driven test with the remainder identified via  routine 
testing (at the blood bank, community events, etc. ). 
Among 120 treatment-naïve individuals, 2.5% were 
categorized as immune tolerant, 11.7% were immune 
active, 35.6% were inactive carriers, and 46.7% had 
an indeterminate phenotype. Per WhO guidelines, 13 
(10.8%) were eligible for immediate antiviral therapy. 
The odds of eligibility were eight times higher for those 
diagnosed at clinical vs  routine settings (adjusted odds 
ratio, 8.33; 95%CI: 2.26-29.41). Among 40 treatment-
experienced hBV patients, virtually all took tenofovir, 
and a history of mild side effects was reported in 20%. 
Though reported adherence was good, 12 of 29 (41.4%) 
had HBV DNA > 20 IU/mL. 
CONCLUSION
Approximately one in ten HBV-monoinfected Zambians 
were eligible for antivirals. Many had indeterminate 
phenotype and needed clinical follow-up. 
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Core tip: Data to inform the scale-up of hepatitis B 
testing and treatment in Africa are badly lacking. 
Among 120 recently diagnosed hepatitis B surface 
antigen-positive and HIV negative adults in Zambia, 
Southern Africa, 10% met the WHO’s criteria for im-
mediate antiviral therapy and an additional 40% had an 
“indeterminate” hepatitis B virus (hBV) phenotype with 
either elevated alanine aminotransferase or hBV DNA 
> 2000 IU/mL. Among 40 additional patients who were 
antiviral therapy-experienced (primarily with tenofovir), 
tolerability and adherence were good; however, nearly 
half had incomplete hBV DNA suppression. Effective 
approaches to retain antiviral-ineligible HBV patients in 
care will be important in Zambia.
Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, 
Chilengi R, Wandeler G, Mulenga J, Chisenga T, Bhattacharya 
D, Saag MS, Foster G, Fried MW, Kelly P. Chronic hepatitis B 
virus monoinfection at a university hospital in Zambia. World J 
Hepatol 2018; 10(9): 622-628  Available from: URL: http://www.
wjgnet.com/1948-5182/full/v10/i9/622.htm  DOI: http://dx.doi.
org/10.4254/wjh.v10.i9.622
INTRODUCTION
In Africa, approximately 60 million individuals are 
chronically infected with hepatitis B virus (HBV). In­
formed by Asian and European data, international 
recommendations were developed to guide policyma­
kers and implementers on diagnosis and treatment 
of chronic HBV in resource­constrained settings[1­3]. 
In settings with hepatitis B surface antigen (HBsAg) 
positivity > 2%, both general population testing and 
targeted testing of populations with higher disease 
burden are recommended; however, limited real world 
data from Africa are available. In addition, understand­
ing the proportion of patients diagnosed with chronic 
HBV infection who would benefit from antiviral therapy 
in African settings is not well­established.
Several recent studies have informed scale­up of 
HBV treatment in Africa. In Zambia, integration of HBsAg 
testing into a population­based HIV survey revealed 5.6% 
of adults and 1.3% of children to be HBsAg­positive 
(Zambian Ministry of Health, 2016 #599). A research 
program in Gambia demonstrated the feasibility of 
community screening, linkage to a comprehensive liver 
evaluation, and initiation of antiviral treatment[4]. Among 
potential key populations (sex workers and men who 
have sex with men) in West Africa and adults in Ethiopia, 
approximately 10% met criteria for antiviral therapy but 
another 50% had markers requiring longitudinal follow­
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up[5]. Building on these and other studies, we established 
an observational cohort study at a referral hospital in 
Lusaka, Zambia. We described where Zambians are 
currently being tested for HBV and among those with no 
prior HBV treatment, we categorized patients into the 
classical stages of HBV using biochemical, virological, 
and non­invasive markers of liver fibrosis. We also 
estimated patient eligibility for antivirals according to 
international guidelines. Among patients already taking 
antiviral therapy, we described medication side effects, 
adherence, and viral suppression.
MATERIALS AND METHODS
Study setting and participant recruitment
In Zambia, 5.6% of adults and 1.3% of children are 
estimated to be HBsAg­positive[6], and HBV genotypes 
A1 and E are present at nearly equal proportions[7]. 
HBsAg testing is part of the evaluation of signs or sym­
ptoms of liver disease, and routine testing in Zambia 
occurs at several settings, including at the blood bank, 
during community screening events (sometimes inte­
grated with HIV testing), and as part of medical check­
ups to obtain a driving license, enroll in college, start 
a new job, etc. Following an HBsAg­positive diagnosis, 
some Lusaka area residents are referred to Univers­
ity Teaching Hospital (UTH), a public tertiary care and 
academic medical facility with > 1000 inpatient beds 
located in Zambia’s capital of Lusaka. At UTH, the 
Department of Internal Medicine hosts a weekly liver 
clinic that is staffed by three gastroenterology­trained 
physicians and provides specialty care for patients with 
acute and chronic liver disease, hepatic lesions, and 
portal hypertension. 
From August 23, 2016 to August 18, 2017, after 
obtaining the required ethical and government appro­
vals, 160 HBsAg­positive HIV­negative adults (18+ years 
old) were enrolled in a cohort study at the UTH liver 
clinic. HIV­HBV coinfected individuals identified during 
recruitment for the cohort were referred for immediate 
linkage to and initiation of antiretroviral therapy accord­
ing to national guidelines[8]. We excluded patients from 
provinces outside of Lusaka to reduce losses to follow­
up. Participants provided written informed consent to be 
followed for up to five years.
Study measures
Although specific HBV management guidelines are li­
mited in Zambia, international standards of care are 
followed. At cohort enrollment, we performed a comple­
te physical examination, including vital signs and body 
mass index (BMI), and extracted data from participants’ 
medical records related to HBV testing, treatment, 
laboratory and imaging tests, and liver biopsy results 
when available. A standardized questionnaire was used 
to document sociodemographic information, comorbid 
conditions, and to screen for and quantify alcohol con­
sumption using the alcohol use disorders identification 
test­consumption (AUDIT­C)[9]. Among those already on 
antiviral drugs for HBV at cohort enrollment, we asses­
sed current or prior drug side effects and self­reported 
medication adherence in the past 7 d. 
Blood was collected for measurement of serum 
transaminases, hemoglobin, platelet count, hepatitis 
B e­antigen (HBeAg), and HBV viral load, which was 
determined using either the Roche COBAS AmpliPrep/
COBAS Taqman platform (Pleasanton, CA, United States) 
or an in­house real time PCR assay[10]. We measured 
liver stiffness non­invasively with the Aspartate Amino­
transferase (AST)­to­platelet ratio index[11] and with 
transient elastography (TE; Fibroscan 402, Echosens, 
Paris, France). TE was performed by a nurse or physician 
trained according to manufacturer guidelines and with 
experience performing > 500 tests. Testing for hepatitis 
C and hepatitis delta was not routinely performed as they 
are rare in Zambia[12,13]. 
Statistical analysis
Among treatment­naïve patients (i.e., no prior history 
of antiviral therapy), we described demographics and 
clinical features stratified by type of HBsAg test (clinical 
or routine). We compared baseline characteristics mea­
sured on categorical scale between clinical and routine 
diagnosis using Fisher’s exact test. For comparison of 
median between the two groups, we used Wilcoxon rank 
sum test. Obesity was BMI > 30 and unhealthy alcohol 
consumption was AUDIT­C of 4+ for men and 3+ for 
women. Among antiviral naïve participants, we described 
HBV viral loads, HBeAg, serum transaminase levels, and 
the proportion of patients with cirrhosis. In our primary 
analysis, we defined elevated ALT as > 30 U/L for men 
and > 20 U/L for women per WHO recommendations[3]. 
We defined persistently elevated ALT as any degree of 
baseline ALT elevation plus an elevated measurement at 
> 60 d prior to baseline. Significant fibrosis (equivalent 
to Metavir fibrosis stages F2-4) was defined as liver sti-
ffness measurement (LSM) of 7.9­9.5 kPa based on a 
validation study in West Africa[14]. We defined cirrhosis as 
having at least one of the following: APRI > 2.0[11], LSM 
> 9.5 kPa[14], or decompensated cirrhosis on physical 
examination defined by the presence of ascites.
Using ALT, HBeAg, and HBV DNA at enrollment, we 
categorized treatment­naïve participants into one of 
the classical stages of chronic HBV infection. Immune 
tolerant stage was defined as HBeAg-positivity, normal 
ALT, and HBV DNA > 20000 IU/mL. Immune active 
HBV was defined as either HBeAg­positive, elevated 
ALT, and HBV DNA > 20000 IU/mL or HBeAg­negative/
unknown with elevated ALT and HBV DNA > 2000 IU/
mL. Inactive carriers were those with HBeAg­negative/
unknown status, normal ALT, and HBV DNA < 2000 
IU/mL. Participants not categorized into one of these 
three stages were considered to have an indeterminate 
phenotype[15]. We repeated this categorization using the 
“conventional” ALT upper limit of normal (i.e., 40 IU/
mL). We compared unhealthy alcohol use and obesity 
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between indeterminate patients with HBV DNA < 2000 
and ALT elevation and inactive carriers using a χ2 test.
We determined eligibility for antiviral therapy if pa­
tients met one of these criteria based on WHO guide­
lines: (1) decompensated cirrhosis; (2) APRI > 2.0; or 
(3) HBV DNA > 20000 IU/mL with ALT elevation and 
age > 30 years. We also assessed treatment eligibi­
lity per European Association for Study of the Liver 
(EASL) criteria[2] as follows: (1) cirrhosis by physical 
examination (with or without decompensation) and 
detectable HBV DNA; (2) HBeAg­positive and age > 
30 years; (3) LSM > 7.9 and HBV DNA > 2000 IU/mL, 
or (4) ALT > 80 U/L and HBV DNA > 20000 IU/mL. 
We compared treatment eligibility, per WHO criteria, 
between those who were diagnosed with a clinically­
driven vs routine HBsAg test using logistic regression 
and adjusting for age and sex.
Among treatment experienced patients, we descri­
bed antiviral therapies received, time on therapy, history 
of side effects, and self­reported adherence. We reported 
the proportion with viral suppression (VS) defined as 
HBV DNA < 20 IU/mL among those on therapy for 2+ 
years. Analyses were performed using Stata version 
14 (Statacorp, College Station, TX, United States). 
The statistical review of the study was performed by 
a biomedical statistician. The cohort was approved by 
the ethics committees at University of Zambia (Lusaka, 
Zambia) and University of Alabama at Birmingham 
(Birmingham, AL, United States). 
RESULTS
Median age was 33 years (IqR, 26­42), 115 (71.9%) 
were men, and the majority (n = 84, 52.6%) were 
recently diagnosed with HBV. The majority were dia­
gnosed at routine HBsAg testing during community/
routine medical check­ups (n = 58; 36.2%) or at the 
blood bank, while 49 (30.6%) were tested due to signs/
symptoms of possible liver disease (i.e., clinical test). 
Current alcohol consumption at “unhealthy levels” was 
reported by 19 (12.2%) participants. At enrollment, 
120 (75.0%) were antiviral therapy naïve. Serum tran­
saminases were available for 145 (90.6%) and 104 
(65.0%) had a prior ALT measurement available at 
a median of 308 d (IqR, 62­469) before enrollment. 
HBeAg testing was performed for 143 (89.4%), 149 
(93.1%) had an HBV DNA measurement, and 97 
(60.6%) underwent TE. A description of treatment 
naïve patients by HBsAg test type (routine vs clinical) is 
shown in Table 1.
Among 120 treatment naïve patients, 5 (4.2%) 
had decompensated cirrhosis (i.e., ascites) by physical 
examination. Among the 62 with sufficient data, median 
APRI was 0.29 (IqR, 0.18­0.51) and 4 (6.4%) had 
APRI > 2.0. Among the 69 that underwent TE, median 
LSM was 6.3 kPa (IqR, 4.8­8.3), 6 (8.7%) had LSM 
suggestive of significant fibrosis, and 14 (20.3%) had 
LSM suggestive of cirrhosis. A cumulative 17 (14.2%) 
patients had cirrhosis by either physical examination, 
APRI, or TE. Median ALT was 23 (IqR, 17­36) and 44 
(40.7%) had an elevated ALT at enrollment based on 
WHO­recommended thresholds. Among the 66 with 
serial ALT levels, 30 (45.4%) had persistently normal 
ALT, 20 (30.3%) had intermittently elevated ALT, and 
16 (24.2%) had persistently elevated ALT. Median HBV 
DNA level was 232 IU/mL (IqR, 23­3495) and viral loads 
were low (i.e., < 2000 IU/mL) for 77 patients (69.4%), 
moderate (2000­20000 IU/mL) for 16 (14.4%), and 
high (> 20000 IU/mL) for 18 (16.2%). HBeAg­positi­
vity was present in 18 (18.9%), and among HBeAg­
positives, 9 (50.0%) had high and 5 (27.8%) had 
moderate HBV DNA levels with 4 at HBV DNA < 2000 
IU/mL. 
Using baseline ALT, HBV DNA, and HBeAg, we 
categorized 3 (2.5%) treatment­naïve patients as 
immune tolerant, 14 (11.7%) as immune active, 47 
(35.6%) as inactive carriers, and 56 (46.7%) as having 
indeterminate stage. While 18 of 56 were consider­
ed indeterminate due to a missing ALT, HBV DNA, or 
HBeAg, 29 had HBV DNA < 20000 IU/mL with eleva­
ted ALT and 7 had HBV DNA > 20000 with normal ALT. 
Elevated ALT in patients with indeterminate stage could 
not be attributed to overweight/obesity or unhealthy 
alcohol use, as rates of these were similar to those of 
inactive carriers (data not shown). After applying the 
conventional ALT threshold (i.e., 40 IU/mL), there were 
6 (5.0%) immune active patients, 10 (8.3%) immune 
active patients, 65 (54.2%) inactive carriers, and 39 
(32.5%) with an indeterminate phenotype. 
According to WHO guidelines, 13 (10.8%) treatment 
naïve patients were deemed to be eligible for antiviral 
therapy at cohort enrollment (Table 2). Of these, five 
became eligible for decompensated cirrhosis, two for 
APRI > 2.0, and six for HBV DNA > 20000 IU/mL with 
ALT elevation and age > 30 years. Among patients 
diagnosed during a routine HBsAg­test, 4 (4.6%) met 
WHO treatment criteria vs 9 (29.0%) of those with 
clinically­driven HBsAg testing. After adjusting for age 
and sex, there was 8 times higher odds of treatment 
eligibility for clinically vs routinely­diagnosed patients 
(adjusted odds ratio, 8.33; 95%CI: 2.26­29.41). By 
EASL guidelines, 21 (17.5%) were eligible for antiviral 
therapy.
Among 40 treatment­experienced patients, 31 were 
currently taking antivirals at enrollment with the majority 
(85%) on fixed dose combination TDF plus 3TC. Median 
time on therapy was 12.2 mo (IqR, 5.0­24.3). Al­
though complete medical records were not available 
for all patients, many treatment­experienced patients 
had a history of significant fibrosis/cirrhosis at time of 
initiation. A minority of patients (n = 6; 20.0%) reported 
at least one side effect in the past/present attributed 
to antivirals, including nausea, diarrhea, skin rash, 
itchiness, dizziness, drowsiness, or mild headache. 
Among those on therapy at enrollment, 17 of 29 (58.6%) 
had complete HBV DNA suppression including 5 of 9 
with 2+ years on treatment. Among the four individu­
als with HBV DNA non­suppression during long­term 
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therapy, all HBV DNA levels were < 2000 IU/mL. Among 
those currently on antivirals, median adherence was 
100% but 12.5% reported missing at least one dose in 
the prior 7 d. 
DISCUSSION
Approximately 1 in 10 Zambian adults with HBV mo­
noinfection met international guidelines for immediate 
antiviral therapy, and an additional half had either 
elevated ALT or HBV DNA > 2000 IU/mL, suggesting 
the need for further follow­up. Participants diagnosed 
on suspicion of having HBV were more likely to require 
therapy compared to those HBsAg tested at routine 
settings. Antiviral therapy was well tolerated among 
treatment­experienced participants; however, a subset 
had HBV DNA non­suppression. These data are some 
of the first data on modern HBV treatment in Southern 
Africa and provide insights around the scale­up of 
testing for and treatment of chronic HBV infection in 
Africa.
While many chronic HBV patients in Zambia had 
elevated ALT, relatively few qualified for immediate 
antiviral therapy when we applied international guide­
lines. By WHO guidelines around 10% of treatment­
naïve patients met criteria and by EASL criteria this was 
closer to 20%. These results are supported by Gambian 
data where 4.4% in the community and 9.7% of blood 
donors met EASL criteria[4]. In a smaller study of female 
sex workers, men who have sex with men, and inmates 
in West Africa, 10.0% were also treatment­eligible 
based on modified WHO criteria[5]. Taken together these 
research data suggest that the WHO criteria are very 
stringent and might be missing some patients who could 
benefit from antiviral therapy. Although not surprising, 
we also observed that symptomatic patients were more 
likely to meet treatment eligibility compared to those 
tested in routine settings. Further data are needed 
to understand the most efficient way to identify HBV 
patients who would benefit from antiviral therapy in 
Zambia and similar settings.
Based on their enrollment values, 35% of our par­
ticipants were classified as inactive carriers and half had 
indeterminate HBV phenotypes. Identification of inactive 
carriers, a group at low risk to progress to cirrhosis or 
develop HCC[16], is useful in programmatic settings in 
Africa. For example, at an HBV treatment program in 
Ethiopia, inactive carriers (also representing around one­
third of patients) will be discharged from care after one 
year in order to focus resources on those more likely to 
benefit from therapy[17]. Unfortunately, our cohort and 
others have reported that a substantial percentage of 
patients cannot be initially categorized as needing or 
not needing therapy (i.e., indeterminate phenotype). In 
Senegal, 53% did not qualify for antivirals but had either 
significant fibrosis, raised ALT, or significant HBV DNA 
levels[5]. In the HBV Research Network (HBRN) in North 
America, 38% had indeterminate phenotype at base­
line and will be followed longitudinally[15]. Similar to the 
HBRN, most patients with indeterminate disease stage 
Table 1 Baseline characteristics of treatment-naïve hepatitis B monoinfected adults referred to a university hospital in Zambia 
according to setting of hepatitis B virus diagnosis
Clinical diagnosis (n  = 31) Routine diagnosis (n  = 89) P  value
Median age, in years   37 (29-42)   33 (26-41)   0.15
Male sex 22 (71.0) 63 (70.8)   0.99
Education level completed
   None to 6th grade   5 (16.1) 3 (3.4)    0.05a
   7th to 12th grade 14 (45.2) 49 (55.1)
   College 12 (38.7) 37 (41.6)
Lifetime alcohol abstinence 13 (41.9) 36 (40.9)   0.92
Herbal medicine use, past month   7 (31.8) 14 (16.3)   0.10
Body mass index
   < 25 23 (76.7) 56 (62.9)   0.35
   25-30   5 (16.7) 20 (22.5)
   > 30 2 (6.7) 13 (14.6)
HBV DNA level, IU/mL
   < 20   4 (15.4) 21 (24.7)   0.12
   20-1999 10 (38.5) 42 (49.4)
   2000-19199   4 (15.4) 12 (14.1)
   ≥ 20000   8 (30.8) 10 (11.8)
HBeAg positive 11 (37.9) 11 (14.5)      0.0081
Median ALT, in U/L (IQR)   22 (17-28)   23 (17-36)   0.82
Elevated ALT   8 (32.0) 36 (43.4)   0.31
AST-to-platelet ratio index ≥ 2.0   4 (21.1) 0      0.0021
Liver stiffness measurement in kPa
   < 7.9   4 (25.0) 45 (84.9)   < 0.0011
   7.9-9.5   2 (12.5) 4 (7.6)
   > 9.5 10 (62.5) 4 (7.6)
1Data with statistical significance. HBV: Hepatitis B virus; ALT: Alanine aminotransferase. All values are n (%) or median (IQR).
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in Zambia had elevated ALT with HBV DNA < 20000 
IU/mL, suggesting non­HBV reasons for ALT elevation. 
Although we did not find that they were correlated with 
having indeterminate stage, fatty liver and hazardous 
alcohol use are potential causes of elevated ALT in HBV 
patients. Longitudinal follow­up to ascertain whether 
patients of indeterminate stage develop treatment 
indications or become inactive carriers is needed in 
Africa to guide HBV policy[5]. 
Our data from treatment­experienced Zambians 
with chronic HBV monoinfection support the feasibility 
of longitudinal treatment with antiviral therapy in African 
settings. TDF + XTC was the most common regimen 
as this fixed­dose combination drug is found in large 
supply in Zambia to treat and prevent HIV/AIDS. We 
documented HBV DNA non­suppression among the 
small group on long­term therapy which requires further 
follow­up. We presumed suboptimal adherence as the 
mechanism, although most of our patients self­repor­
ted good adherence in the prior week. Our data are con­
trasted by the PROLIFICA study in the Gambia where 
43 of 47 (91.5%) tenofovir­treated HBV monoinfected 
individuals achieved viral suppression at one year[4]. 
Lower HBV DNA suppression in our cohort may reflect 
differences in study design (clinical trial vs hospital 
cohort) or could reflect HBV genotypic differences as 
Gambia has predominantly HBV genotype E and Zambia 
has both E and A1, a genotype that rapidly developed 
lamivudine­resistance in Malawi[18]. 
This study has several limitations. Most importantly, 
our cohort is based at one site in Zambia and may not 
represent other HBV­infected populations. Our cohort 
is hospital­based and enriched for sicker patients eviden­
ced by the fact that participants referred from clinical 
settings were eight times more likely to be treatment­
eligible compared to other HBsAg­positives. To offset 
this, we also characterized a subset of participants 
diagnosed at routine settings such as the blood bank and 
a population­based survey. Finally, we had incomplete 
laboratory and clinical data that led to incomplete eva­
luation of some patients and inflated our estimate of 
the proportion with indeterminate HBV. We believe the 
missing data occurred at random and would not have 
introduced bias into the distribution of HBV stages.
In summary, an HBV monoinfection cohort was es­
tablished at a referral hospital in Zambia to begin to 
answer a number of clinical and operational questions 
around HBV treatment in Africa. We observed that 1 in 
10 patients who underwent comprehensive assessment 
met the WHO criteria for therapy, although the number 
was higher among those with signs/symptoms and 
lower among those diagnosed during routine HBsAg 
testing. These data support scale­up of HBV testing 
and treatment in Africa, but further operational and 
clinical research is needed to define the most effective 
and efficient way to reduce HBV-related mortality and 
morbidity. 
ARTICLE HIGHLIGHTS
Research background
Africa has 60 million individuals living with chronic hepatitis B virus (HBV) 
infection yet limited data to inform how to identify, link to care, and treat them to 
reduce the burden of cirrhosis and liver cancer.
Research motivation
Not all HBV patients need antivirals. Estimates on how many do will guide 
policy implementation. Also, few data are available on patient adherence, 
retention, and viral suppression with current antiviral drugs.
Research objectives
Our objective was to perform a comprehensive clinical assessment on chronic 
HBV-infected adults in Zambia and apply international criteria to learn what 
percentage may need antiviral drugs. In those already on antivirals, we 
measured the viral control. 
Research methods
At a university hospital in Zambia, a cross-sectional assessment of adults (18+ 
years old) who were hepatitis B surface antigen positive and HIV negative 
was undertaken during 2016-2017. We used tests available in upper-income 
settings such as HBV DNA testing and transient elastography to assess HBV in 
these patients.
Research results
One hundred and sixty enrolled in the study, including 120 who were recently 
diagnosed with HBV and 40 already on antiviral drugs. The average age 
was 33, and 72% were men. We found that 1 in 10 met the World Health 
Organization guidelines to start antivirals; however, nearly 1 in 2 had at least 
one finding that would need clinical follow-up. Patients diagnosed because of 
signs or symptoms of HBV were slightly more likely to need antivirals compared 
to those diagnosed via routine testing (such as at the blood bank). Among those 
Table 2 Hepatitis B virus stage and eligibility for immediate antiviral therapy among treatment-naïve Zambian adults with chronic 
hepatitis B virus infection n  (%)
Overall (n  = 120) Clinical diagnosis (n  = 31) Routine diagnosis1 (n  = 89) P 2
HBV stage Immune tolerant 3 (2.5) 2 (6.4) 1 (1.1)    0.16
Immune active 14 (11.7)   4 (12.9) 10 (11.2)  0.8
Inactive carrier 47 (35.6)   7 (20.0) 40 (41.2)     0.023
Indeterminate 56 (46.7) 18 (58.1) 38 (42.7)    0.14
Eligibility for immediate 
therapy per guidelines
WHO 2015 guidelines 13 (10.8)   9 (29.0) 4 (4.5)  < 0.013
EASL 2017 guidelines 21 (17.5) 12 (38.7)   9 (10.1)  < 0.013
1Routine diagnosis was defined as being tested for hepatitis B surface antigen at the blood bank, antenatal care, a community screening event, or as part of 
a routine medical check-up; 2A χ 2 test was used to compare clinically and routinely HBV-diagnosed participants; 3Data with statistical significance. HBV: 
Hepatitis B virus; WHO: World Health Organization; EASL: European Association for Study of the Liver.
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already on the antivirals, few had side effects; however, 41% did not completely 
control their viral load. 
Research conclusions
This is the first Southern African study to apply international HBV criteria. 
Research perspectives
Additional data are needed on whether those with high ALT or viral loads at 
baseline will later need antivirals. HBV testing that focuses on symptomatic 
individuals could be more efficient (than routine testing for all) to find those 
needing treatment but more information is needed.
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